Eledon Pharmaceuticals
ELDN
20 hedge funds and large institutions have $18.2M invested in Eledon Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
25% more funds holding
Funds holding: 16 → 20 (+4)
0.01% less ownership
Funds ownership: 41.34% → 41.33% (-0.01%)
33% less capital invested
Capital invested by funds: $27.2M → $18.2M (-$9.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$326K |
| 2 |
Renaissance Technologies
New York
|
+$317K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$198K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$164K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$99.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$1.1M |
| 2 |
DC
Derby & Company
Newton,
Massachusetts
|
-$207K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$129K |
| 4 |
D.E. Shaw & Co
New York
|
-$8.27K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.76K |
ELDN Hedge Fund Activity: Q3 2018 in Review
20 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2018, worth a combined $18.2M — down 33% from $27.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ELDN positions and 2 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $326K. The largest seller was Lyon Street Capital, cutting an estimated $1.1M.
- 20 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2018, up from 16 in Q2 2018.
- Funds reported $18.2M of Eledon Pharmaceuticals stock for Q3 2018, down 33% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q3 2018 and 2 closed out, a net change of +4 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2018 was Vanguard Group, an estimated $326K added.
- The largest Eledon Pharmaceuticals seller in Q3 2018 was Lyon Street Capital, an estimated $1.1M sold.
Based on aggregated 13F filings for Q3 2018.